OTCMKTS:ULGX

Urologix Competitors

$0.0052
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.02
Volume8,000 shs
Average Volume87,707 shs
Market Capitalization$110,916.00
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Competitors

Urologix (OTCMKTS:ULGX) Vs. SCIE, ECTE, AKSY, ESMC, HRTT, and IVVI

Should you be buying ULGX stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Urologix, including SpectraScience (SCIE), Echo Therapeutics (ECTE), Aksys (AKSY), Escalon Medical (ESMC), Heart Tronics (HRTT), and Ivivi Technologies (IVVI).

Urologix (OTCMKTS:ULGX) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Urologix and SpectraScience, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
SpectraScience0000N/A

Earnings & Valuation

This table compares Urologix and SpectraScience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
SpectraScienceN/AN/AN/AN/AN/A

Volatility & Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Profitability

This table compares Urologix and SpectraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
SpectraScienceN/AN/AN/A

Summary

Urologix beats SpectraScience on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Urologix and Echo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
Echo Therapeutics0000N/A

Volatility & Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its stock price is 609% more volatile than the S&P 500.

Earnings & Valuation

This table compares Urologix and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Urologix and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Summary

Echo Therapeutics beats Urologix on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Urologix and Aksys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
AksysN/AN/AN/A

Volatility and Risk

Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, indicating that its stock price is 776% less volatile than the S&P 500.

Valuation & Earnings

This table compares Urologix and Aksys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
AksysN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Urologix and Aksys, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
Aksys0000N/A

Summary

Urologix beats Aksys on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Escalon Medical (OTCMKTS:ESMC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Urologix and Escalon Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
Escalon Medical$9.40 millionN/A$-650,000.00N/AN/A

Urologix has higher earnings, but lower revenue than Escalon Medical.

Volatility & Risk

Urologix has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Escalon Medical has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Urologix and Escalon Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
Escalon Medical0000N/A

Profitability

This table compares Urologix and Escalon Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
Escalon Medical-15.54%-136.63%-26.09%

Summary

Urologix beats Escalon Medical on 4 of the 5 factors compared between the two stocks.

Heart Tronics (OTCMKTS:HRTT) and Urologix (OTCMKTS:ULGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Volatility & Risk

Heart Tronics has a beta of 1024.78, indicating that its share price is 102,378% more volatile than the S&P 500. Comparatively, Urologix has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Heart Tronics and Urologix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heart Tronics0000N/A
Urologix0000N/A

Profitability

This table compares Heart Tronics and Urologix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heart TronicsN/AN/AN/A
UrologixN/AN/AN/A

Valuation & Earnings

This table compares Heart Tronics and Urologix's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heart TronicsN/AN/AN/AN/AN/A
UrologixN/AN/AN/AN/AN/A

Summary

Heart Tronics beats Urologix on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Ivivi Technologies (OTCMKTS:IVVI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Urologix and Ivivi Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
Ivivi Technologies0000N/A

Profitability

This table compares Urologix and Ivivi Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
Ivivi TechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Urologix and Ivivi Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
Ivivi TechnologiesN/AN/AN/AN/AN/A


Urologix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SCIE
SpectraScience
0.5$0.00flat$265,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.02flat$234,000.00N/A0.00Gap Down
AKSY
Aksys
0.0$0.05flat$0.00N/A0.00Gap Down
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.39flat$0.00$9.40 million-6.50Gap Up
HRTT
Heart Tronics
0.0$0.02flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00Gap Up
PECN
Photoelectron
0.2$0.00flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.